EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE ‐042 China study

Fünfjahresergebnisse von Pembrolizumab versus Chemotherapie bei chinesischen Patient:innen mit nicht kleinzelligem Lungenkarzinom und PD-L1-Tumorproportionsscore ≥1 %: KEYNOTE-042 China-Studie

Yi-Long Wu iD, Li Zhang, Yun Fan iD, JianYing Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Carmen González Arenas und 3 weitere

International Journal of Cancer · 01.05.2026 · 158 (9) · 2429-2439

DOI: 10.1002/ijc.70265 ↗

Auf einen Blick

Bei chinesischen Patient:innen mit zuvor unbehandeltem lokal fortgeschrittenem oder metastasiertem NSCLC verlängerte Pembrolizumab nach 5 Jahren das Gesamtüberleben gegenüber Chemotherapie. Die Sicherheit war beherrschbar.

Fragestellung

Verbessert Pembrolizumab im Vergleich zur Chemotherapie das Gesamtüberleben bei chinesischen Patient:innen mit zuvor unbehandeltem lokal fortgeschrittenem oder metastasiertem NSCLC und PD-L1-TPS ≥1 %?

Methode

Phase-3-Studie mit 262 Patient:innen; Randomisierung 1:1 zu Pembrolizumab oder Chemotherapie; mediane Nachbeobachtung 63,7 Monate.

Ergebnisse

Pembrolizumab verbesserte das OS in den Subgruppen mit PD-L1-TPS ≥50 % (HR 0,65; 95 %-KI 0,45–0,93), ≥20 % (0,67; 0,49–0,91) und ≥1 % (0,66; 0,51–0,87). Grad-3-bis-5-therapiebedingte UAW: 19,5 % vs. 68,8 %.

Schlussfolgerung der Autor:innen

Nach 5 Jahren zeigte Pembrolizumab weiterhin ein verbessertes OS gegenüber Chemotherapie bei akzeptabler Sicherheit bei chinesischen Patient:innen mit zuvor unbehandeltem lokal fortgeschrittenem oder metastasiertem PD-L1-positivem NSCLC.

Kernaussagen

  • OS-Vorteil von Pembrolizumab in allen drei PD-L1-Subgruppen
  • HR für PD-L1-TPS ≥1 %: 0,66 (95 %-KI 0,51–0,87)
  • Grad-3-bis-5-therapiebedingte UAW seltener als unter Chemotherapie

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, online erschienen am 31.12.2025. Verfasst von Yi-Long Wu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzh…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Humanized, Lung Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the phase 3 KEYNOTE‐042 China study of participants enrolled in China in the global KEYNOTE‐042 (NCT02220894) and China extension (NCT03850444) studies, pembrolizumab improved overall survival (OS) versus chemotherapy in locally advanced or metastatic non‐small‐cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD‐L1) tumor proportion score (TPS) ≥50% (hazard ratio [HR], 0.63; 95% CI, 0.43–0.94), ≥20% (0.66; 0.47–0.92), and ≥1% (0.67; 0.50–0.89). We present outcomes from this study after 5 years of follow‐up. Chinese participants with previously untreated locally advanced or metastatic NSCLC with PD‐L1 TPS ≥1% without EGFR or ALK alterations were eligible. Participants were randomized 1:1 to pembrolizumab 200 mg every 3 weeks for up to 35 cycles or carboplatin plus paclitaxel or pemetrexed with optional pemetrexed maintenance (nonsquamous only). Primary endpoints were OS in the PD‐L1 TPS ≥50%, ≥20%, and ≥1% subgroups. Median follow‐up was 63.7 (range, 56.3–72.6) months among 262 participants (pembrolizumab, n = 128; chemotherapy, n = 134) included in this study. Pembrolizumab prolonged OS versus chemotherapy in participants with PD‐L1 TPS ≥50% (HR, 0.65; 95% CI, 0.45–0.93), ≥20% (0.67; 0.49–0.91), and ≥1% (0.66; 0.51–0.87). Grade 3 to 5 treatment‐related AEs occurred in 19.5% and 68.8% of participants in the pembrolizumab and chemotherapy groups, respectively. In conclusion, after 5 years of follow‐up, pembrolizumab continued to demonstrate improved OS versus chemotherapy with manageable safety in Chinese participants with previously untreated locally advanced or metastatic NSCLC that expressed PD‐L1. These data further support pembrolizumab monotherapy as a standard of care for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAntibodies, Monoclonal, HumanizedLung NeoplasmsB7-H1 AntigenAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedChinaAgedAdultFollow-Up StudiesTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

chemotherapynon‐small‐cell lung cancerpembrolizumabprogrammed cell death ligand 1

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Respiratory Medicine Department, Peking Union Medical College Hospital, Beijing, China.
  • Department of Thoracic Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
  • Department of Respiratory Medicine, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Oncology Department, The First Hospital of Jilin University, Changchun, China.

ORCID-Profile: Yi-Long Wu, Yun Fan

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Wu, Y. L., Zhang, L., Fan, Y., Zhou, J., Zhang, L., Zhou, Q., Li, W., Hu, C., Chen, G., Zhang, X., Zhou, C., Arenas, C. G., Chen, Z., Yu, W. C., & Mok, T. S. K. (2026). Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE ‐042 China study. International Journal of Cancer, 158(9), 2429-2439. https://doi.org/10.1002/ijc.70265

Vancouver

Wu YL, Zhang L, Fan Y, Zhou J, Zhang L, Zhou Q, et al. Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE ‐042 China study. International Journal of Cancer. 2026;158(9):2429-2439. doi:10.1002/ijc.70265

BibTeX
@article{Wu2026,
  author = {Wu, Yi-Long and Zhang, Li and Fan, Yun and Zhou, JianYing and Zhang, Li and Zhou, Qing and Li, Wei and Hu, ChengPing and Chen, GongYan and Zhang, Xin and Zhou, CaiCun and Arenas, Carmen González and Chen, Zhenghong and Yu, Wen Cheng and Mok, Tony S K},
  title = {Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE ‐042 China study},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {158},
  number = {9},
  pages = {2429--2439},
  doi = {10.1002/ijc.70265}
}
Kostenlos starten →